Efficacy and safety of hetrombopag in the treatment of recombinant human thrombopoietin–resistant thrombocytopenia after allogeneic hematopoietic stem cell transplantation
Our results suggested that hetrombopag is an effective treatment option to promote platelet recovery in patients with posttransplant thrombocytopenia, even in patients resistant to rhTPO.
Authors
- Jifei Dai
- Jing Ni
- Qingsheng Li
- Mingzhen Yang (ORCID: https://orcid.org/0000-0002-9667-1583)
- Hong Jian (ORCID: https://orcid.org/0000-0002-7749-7313)
- ChengXin Luan
- Zhangbiao Long (ORCID: https://orcid.org/0009-0003-0692-1935)
- Xinglin Liang
Institutions
- Capital Medical University (CN)
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1016/j.rpth.2024.102578
- Citations
- 5
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.27
Funders
- Anhui Medical University
- Natural Science Foundation of Anhui Province